What Happened?
Emeryville, CA-based Gritstone Bio Resigned Roman Yelensky as Executive Vice President and Chief Technology Officer
About the Company
Gritstone Bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system`s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.
About the Person
Roman Yelensky is Executive Vice President and Chief Technology Officer at Gritstone Bio. Previously, Roman held various senior IT leadership roles in the industry.
Info Source
News
Short Profile